Proactiveinvestors United Kingdom ImmuPharma PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom ImmuPharma PLC RSS feed en Mon, 22 Jul 2019 00:18:15 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - Immupharma chairman details £2.66mln financing and open label extension study ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13982/immupharma-chairman-details-266mln-financing-and-open-label-extension-study-13982.html Thu, 04 Jul 2019 08:29:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13982/immupharma-chairman-details-266mln-financing-and-open-label-extension-study-13982.html <![CDATA[RNS press release - TR-1: notification of major holdings ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190704070006_14135958/ Thu, 04 Jul 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190704070006_14135958/ <![CDATA[RNS press release - TR-1: notification of major holdings ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190702153311_14133870/ Tue, 02 Jul 2019 15:33:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190702153311_14133870/ <![CDATA[News - ImmuPharma jumps as follow-up study confirms safety of flagship lupus drug ]]> https://www.proactiveinvestors.co.uk/companies/news/223020/immupharma-jumps-as-follow-up-study-confirms-safety-of-flagship-lupus-drug-223020.html ImmuPharma PLC’s (LON:IMM) flagship lupus drug has confirmed its “outstanding and robust safety profile” in a six-month extension study.

The follow-up study was designed to evaluate Lupuzor’s safety and tolerability, and the drug passed with flying colours, with no serious adverse events reported.

WATCH: Immupharma chairman details £2.66mln financing and open label extension study

On top of that, ImmuPharma was also able to show that a third of the patients taking the drug were in remission at the end of the study.

“We are delighted that Lupuzor has again confirmed its robust safety profile and we are confident that Lupuzor has the potential to bring a much-needed treatment to Lupus sufferers around the world,” said chairman Tim McCarthy.

Building knowledge of drug

The follow-up study came about after Lupuzor missed its primary endpoint in a phase III trial last year.

But the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody positive.

Since then, ImmuPharma has been building a data package for the drug in order to boost its chances of regulatory success further down the line.

As well as the extension study, 500 lupus sufferers are being given access to Lupuzor for the next two years as part of a managed access programme (MAP).

After the success of the latest study, if Lupuzor can prove itself again in the MAP, ImmuPharma will look to use the data to get full regulatory approval for the drug, something bosses have previously said they hope to achieve “in the medium term”.

Shares were up 6% to 14.3p in early deals on Friday.

]]>
Fri, 28 Jun 2019 08:30:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223020/immupharma-jumps-as-follow-up-study-confirms-safety-of-flagship-lupus-drug-223020.html
<![CDATA[RNS press release - Update on Lupuzor ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190628070005_14128107/ Fri, 28 Jun 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190628070005_14128107/ <![CDATA[RNS press release - 2019 Annual General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190627133852_14127477/ Thu, 27 Jun 2019 13:38:52 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190627133852_14127477/ <![CDATA[News - ImmuPharma raises around £2.66mln from subscription agreement with institutional investor, Lanstead Capital ]]> https://www.proactiveinvestors.co.uk/companies/news/222836/immupharma-raises-around-266mln-from-subscription-agreement-with-institutional-investor-lanstead-capital-222836.html ImmuPharma PLC (LON:IMM) has raised around £2.66mln from a subscription agreement with institutional investor, Lanstead Capital, together with a related sharing agreement.

The AIM-listed specialist drug discovery and development Company said Lanstead is subscribing for 26,565,200 new ordinary shares at an issue price of 10p each, representing approximately 19% of the company's existing issued share capital. The issue price represents a 26.5% discount to Immupharma’s closing mid-market price on Tuesday.

READ: ImmuPharma continuing to talk with potential partners

The subscription, the maximum amount under the company's existing authorisation, represents a further supportive investment in the company by Lanstead following the £4.43mln it made investment in February 2016, from which the Company ultimately received just over £5.0mln including the additional funds received through a sharing agreement over time.

The sharing agreement with Lanstead, entitles the company to receive back the proceeds on a pro rata monthly basis over a period of 24 months, subject to adjustment upwards or downwards each month depending on the company's share price at the time.

The group said the sharing agreement provides the opportunity for the company to benefit from positive future share price performance. It has also agreed to issue 1,328,290 ordinary shares to Lanstead in connection with entering into the sharing agreement.

Immupharma said the proceeds of the subscription will be used primarily to fund the execution of its corporate strategy, as announced on 7 May 2019, including progressing Lupuzor through both corporate partnerships and regulatory pathways and proactively pursuing the 'spin-off' of the subsidiary companies, Ureka and ELRO, in order to unlock their future potential and enhance value to shareholders.

Commenting on the share subscription, ImmuPharma's Chairman, Tim McCarthy, said: ”Lanstead has been very supportive of the Company since their first investment in 2016 and this latest subscription demonstrates their continued support and the alignment of both the Company and Lanstead's belief of the potential of substantial value enhancement for shareholders in the future execution of the Company's recently stated corporate strategy."

]]>
Wed, 26 Jun 2019 08:19:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222836/immupharma-raises-around-266mln-from-subscription-agreement-with-institutional-investor-lanstead-capital-222836.html
<![CDATA[RNS press release - Subscription to raise £2.66 million ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190626070006_14124413/ Wed, 26 Jun 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190626070006_14124413/ <![CDATA[Media files - Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13612/analyst-sees--clear-rationale--for-immupharma-to-move-forward-with-lupuzor-13612.html Wed, 05 Jun 2019 12:46:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13612/analyst-sees--clear-rationale--for-immupharma-to-move-forward-with-lupuzor-13612.html <![CDATA[RNS press release - Notice of AGM and posting of Report & Accounts ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190604070011_14097072/ Tue, 04 Jun 2019 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190604070011_14097072/ <![CDATA[Media files - Immupharma PLC assessing best route forward for lead drug Lupuzor ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13499/immupharma-plc-assessing-best-route-forward-for-lead-drug-lupuzor-13499.html Tue, 28 May 2019 13:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13499/immupharma-plc-assessing-best-route-forward-for-lead-drug-lupuzor-13499.html <![CDATA[News - ImmuPharma continuing to talk with potential partners ]]> https://www.proactiveinvestors.co.uk/companies/news/220903/immupharma-continuing-to-talk-with-potential-partners-220903.html ImmuPharma PLC (LON:IMM) has confirmed that discussions with potential partners are ongoing as it assess the best route forward for its lead drug.

The results from an extension study of Lupuzor, a treatment for the autoimmune disease Lupus, will feed into the decision making.

WATCH: Immupharma PLC assessing best route forward for lead drug Lupuzor

A readout from the clinical assessment of 62 patients who took part in an earlier phase III trial is expected later this current quarter, the firm confirmed in an update alongside its full-year results.

The results of that final-phase assessment of Lupuzor were inconclusive, but ImmuPharma believes the drug has a part to play in the treatment regimen of sufferers. Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.

Managed access programme on hold 

A planned managed access programme that would have provided patients with Lupuzor even though it doesn’t yet have regulatory sign-off has been put on hold.

This is to allow management to discuss with potential corporate partners and regulatory advisors the best way forward.

In the meantime, the company will focus on other applications in the autoimmune space for the drug, which is also known as P140.

ImmuPharma previously announced plans to merge its Elro and Ureka subsidiaries and it confirmed Friday it will look to out-licence their technologies, or spin off the businesses completely. This would allow the AIM-listed drug developer to concentrate on P140.

Results for the year ended December 31 showed the company posted a £7.2mln loss. More important to followers and would-be investors is cash in the bank, which was £4.9mln at the period-end. The coffers were topped up following a £10mln fundraiser in January.

]]>
Fri, 24 May 2019 07:32:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220903/immupharma-continuing-to-talk-with-potential-partners-220903.html
<![CDATA[RNS press release - FINAL RESULTS ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190524070005_14086035/ Fri, 24 May 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190524070005_14086035/ <![CDATA[RNS press release - Corporate Update - Replacement ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190507081526_14063639/ Tue, 07 May 2019 08:15:26 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190507081526_14063639/ <![CDATA[News - ImmuPharma updates status of talks over lead drug alongside reorganisation ]]> https://www.proactiveinvestors.co.uk/companies/news/219768/immupharma-updates-status-of-talks-over-lead-drug-alongside-reorganisation-219768.html ImmuPharma PLC (LON:IMM) has confirmed it remains in negotiations with potential corporate partners for its lead drug Lupuzor, which has been developed to treat the auto-immune disease lupus.

It also said it is consulting with regulatory advisors on "potential pathways to market".

This follows the not wholly successful conclusion of phase III trials last year, though ImmuPharma believes the drug has market potential.

But, while talks with putative partners and advisors take place, the firm has put on hold a managed access programme for Lupuzor.

An extension study of the drug, meanwhile, is on track to report results this quarter.

Looking at the company’s other activities, management has decided to merge the France-based Elro Pharma and Ureka businesses “with a view to securing external investment either from private equity or through a public listing”.

“This in turn would allow ImmuPharma to focus on Lupuzor and the overall P140 platform for different autoimmune indications,” it added.

Finally, collaboration discussions with a company called Incanthera Limited have ended.

The shares rose 3% to 10.08p.

----adds share price----

]]>
Tue, 07 May 2019 07:58:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219768/immupharma-updates-status-of-talks-over-lead-drug-alongside-reorganisation-219768.html
<![CDATA[RNS press release - Corporate Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190507070008_14063791/ Tue, 07 May 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190507070008_14063791/ <![CDATA[News - ImmuPharma cancer programme talks continue ]]> https://www.proactiveinvestors.co.uk/companies/news/217602/immupharma-cancer-programme-talks-continue-217602.html ImmuPharma PLC (LON:IMM) said a period of exclusivity has run out between it and Incanthera Limited, which allows the ImmuPharma to discuss collaborations with other potential partners for its Nucant cancer programme.

“Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for broader collaboration,” the AIM-listed life sciences group told investors.

READ: ImmuPharma says article shines light on potential of peptide subsidiary

“There can be no guarantee that any agreement will be reached with Incanthera on a broader collaboration.”

An outline deal was inked last September, at which point ImmuPharma took a £2mln stake in Incanthera. The deadline for a definitive agreement was extended from the end of December to the end of March.

]]>
Mon, 01 Apr 2019 07:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217602/immupharma-cancer-programme-talks-continue-217602.html
<![CDATA[RNS press release - Update on Nucant Cancer Programme ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190401070006_14022470/ Mon, 01 Apr 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190401070006_14022470/ <![CDATA[News - ImmuPharma continues to engage with potential corporate partners for Lupuzor, its late-stage treatment for Lupus ]]> https://www.proactiveinvestors.co.uk/companies/news/216447/immupharma-continues-to-engage-with-potential-corporate-partners-for-lupuzor-its-late-stage-treatment-for-lupus-216447.html ImmuPharma PLC (LON:IMM) continues to engage with potential corporate partners for Lupuzor, its late-stage treatment for Lupus, as well as progressing potential collaboration opportunities on its other projects.

In a brief corporate update, the AIM-listed specialist drug discovery and development company said that, following the conclusion of the pivotal Phase III trial earlier in 2018, it continues to look at opportunities which, over the longer term, have the potential of bringing Lupuzor to market.

READ: ImmuPharma says article shines light on potential of peptide subsidiary

The company noted that, together with its partner, it is in the final preparations for the Lupuzor Managed Access Program which will be open to eligible patients in Europe, with further updates to be provided to the market in due course.

It added that the Lupuzor open-label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in the second quarter of 2019.

Nucant Cancer Programme

Turning to other areas of development, ImmuPharma said discussions are continuing on the clinical development collaboration for its Nucant Cancer Programme with - as announced on 31 December 2018 - the exclusivity period having been extended to 31 March 2019, and an update will be provided in due course.

With regards to its Bordeaux based subsidiary, Ureka SARL – which is focusing on transforming peptides into efficient drugs for treatments in a number of therapeutic areas including Type II diabetes - ImmuPharma said continues to look at all options regarding the progression of Ureka's assets.

The firm said this process is ongoing and further updates will be announced as appropriate.

Tim McCarthy, ImmuPharma's chairman said: "We remain focused on creating long term value throughout our portfolio through initiatives including the Managed Access Program for Lupuzor,  whilst the Company continues to engage with industry partners for potential collaboration opportunities on its projects."

]]>
Thu, 14 Mar 2019 07:51:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216447/immupharma-continues-to-engage-with-potential-corporate-partners-for-lupuzor-its-late-stage-treatment-for-lupus-216447.html
<![CDATA[RNS press release - Corporate Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190314070012_14001528/ Thu, 14 Mar 2019 07:00:12 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190314070012_14001528/ <![CDATA[News - ImmuPharma says article shines light on potential of peptide subsidiary ]]> https://www.proactiveinvestors.co.uk/companies/news/215281/immupharma-says-article-shines-light-on-potential-of-peptide-subsidiary-215281.html ImmuPharma PLC (LON:IMM) said peer-reviewed journal Nature Communications has carried an article assessing the potential of Urelix, a technology developed by its subsidiary Ureka.

The periodical has described for the first time the unique properties of oligourea foldamers as tools to improve the pharmaceutical properties of peptides.

There are more than 7,000 naturally occurring peptides that have crucial roles in human physiology, including actions as hormones, neurotransmitters and growth factors.

Around 140 peptide therapeutics are currently being developed, while currently around 60 have been approved by the US Food & Drug Administration generating sales last year of US$30bn.

However, as Dimitri Dimitriou, ImmuPharma's chief executive, pointed out: “Using natural peptides as drugs is not so effective because they are quickly broken down. 

“To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs.”

One of the first areas of focus for the Ureka researchers has been lookalikes for GLP-1, the basis of a number of drugs used to treat type II diabetes and non-alcoholic liver disease.

Scientists are also assessing the potential of using the Urelix to develop cancer drug candidates and as means of improving products already on the market.

The work of the Ureka began in 2014 and the ImmuPharma offshoot has a tie-up with France’s Centre National de la Recherche Scientifique.

]]>
Tue, 26 Feb 2019 07:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215281/immupharma-says-article-shines-light-on-potential-of-peptide-subsidiary-215281.html
<![CDATA[RNS press release - Technology review published-Nature Communications ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190226070027_13981261/ Tue, 26 Feb 2019 07:00:27 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20190226070027_13981261/ <![CDATA[News - ImmuPharma continues to build data package for flagship lupus treatment ]]> https://www.proactiveinvestors.co.uk/companies/news/215247/immupharma-continues-to-build-data-package-for-flagship-lupus-treatment-215247.html  

What it does

ImmuPharma PLC (LON:IMM) specialises in developing drugs for serious medical conditions for which there is a distinct lack of existing treatments.

Its flagship drug is called Lupuzor – a treatment for the autoimmune disease lupus.

The drug missed its primary endpoint in a phase II study last year, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

The results certainly haven’t held back ImmuPharma or its top drug. In fact, boss Tim McCarthy has said that Lupuzor still possesses “blockbuster potential”, meaning it could rack more than US$1bn in annual sales.

After the end of the phase III trial, 62 patients took part in a ‘follow-up’ study – called an open-label extension study. Results from this are expected between April and June.

On top of that, another 500 lupus sufferers are being given access to Lupuzor for the next two years as part of a managed access programme.

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

Blue sky

In the immediate future, results from the Lupuzor follow-up study are due by the end of June, while the managed access programme is set to complete towards the end of 2020.

Should Lupuzor prove itself in those two tests, ImmuPharma will use the data to try to get full regulatory approval the drug, something bosses hope to achieve “in the medium term”.

Lupuzor isn’t ImmuPharma’s only drug going through the clinic. Its Nucant cancer treatment has yielded “promising results” in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mln stake.

A licence agreement between the two is expected to be signed by the end of March, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma has said.

What the boss is saying

]]>
Mon, 25 Feb 2019 15:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/215247/immupharma-continues-to-build-data-package-for-flagship-lupus-treatment-215247.html
<![CDATA[News - ImmuPharma extends exclusivity period for its collaboration talks with Incanthera ]]> https://www.proactiveinvestors.co.uk/companies/news/211797/immupharma-extends-exclusivity-period-for-its-collaboration-talks-with-incanthera-211797.html The exclusivity agreement between ImmuPharma PLC (LON:IMM) and Incanthera Limited, due to expire at midnight today, has been extended to the end of March.

ImmuPharma announced on 7 September a clinical development collaboration for its Nucant cancer programme with specialist oncology development company, Incanthera, but it has yet to finalise the definitive licence agreement'.

REA: ImmuPharma says managed access programme for Lupozor progressing as planned

It is now envisaged that the agreement will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.

"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019,” said Dimitri Dimitriou, the chief executive officer of ImmuPharma.

]]>
Mon, 31 Dec 2018 07:10:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211797/immupharma-extends-exclusivity-period-for-its-collaboration-talks-with-incanthera-211797.html
<![CDATA[RNS press release - Clinical Development Collaboration with Incanthera ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181231070007_13918723/ Mon, 31 Dec 2018 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181231070007_13918723/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181221164102_13913964/ Fri, 21 Dec 2018 16:41:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181221164102_13913964/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181221163619_13913950/ Fri, 21 Dec 2018 16:36:19 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181221163619_13913950/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181220163548_13912097/ Thu, 20 Dec 2018 16:35:48 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181220163548_13912097/ <![CDATA[RNS press release - Appointment of Nominated Adviser ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181217070006_13905326/ Mon, 17 Dec 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181217070006_13905326/ <![CDATA[News - ImmuPharma says managed access programme for Lupozor progressing as planned ]]> https://www.proactiveinvestors.co.uk/companies/news/210762/immupharma-says-managed-access-programme-for-lupozor-progressing-as-planned-210762.html ImmuPharma PLC (LON:IMM) shares rose on Friday as the biopharma firm revealed that the managed access programme (MAP) for Lupozor, its late-stage treatment for auto-immune disease Lupus is progressing as planned.

In an update on corporate activities, the AIM-listed firm said that following analysis of the regulatory processes in EU countries, it is planned to begin patient recruitment for the programme in France and UK and then roll out to other EU countries.

WATCH: ImmuPharma firmly committed to Lupuzor ahead of managed access programme

Tim McCarthy, ImmuPharma’s chairman, said: "We are delighted to be progressing the necessary activities for the Managed Access Programme, allowing Lupus patients early access to Lupuzor.

 “In conjunction, in the medium term we remain focused on achieving the full regulatory approval of Lupuzor, which we are confident has the potential to be a ground-breaking drug for Lupus patients.”

The company also said that, further to the ‘Heads of Terms’ agreement announced on 7 September 2018 regarding a clinical development collaboration for its Nucant cancer programme with specialist oncology development company, Incanthera Limited, the two companies are making good progress in finalising the 'Definitive Licence Agreement' within the exclusivity period up to 31 December 2018.

Ureka evaluation process

ImmuPharma also stated in its announcement of 7 September that it would commence a process of considering all opportunities to divest its Ureka business, and said today that, following this period of review, the firm intends to engage the services of a leading specialist R&D and advisory firm in the sector, to support the evaluation of Ureka's technologies and drug candidates and the development activities for the progression of its assets and the business.

It added: “This process is ongoing and further updates will be announced as appropriate.”

McCarthy commented: "Our Nucant programme and Ureka subsidiary continue to progress with their separate strategies, both having the ultimate goal of achieving value for all stakeholders going forward.”

McCarthy also said that active discussions regarding the appointment of a new NOMAD are ongoing and added: “We look forward to updating the market and shareholders again in the near future."

In early morning trading, ImmuPharma shares were 6% higher at 13p.

]]>
Fri, 07 Dec 2018 08:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210762/immupharma-says-managed-access-programme-for-lupozor-progressing-as-planned-210762.html
<![CDATA[RNS press release - Update on Corporate Activities ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181207070005_13895038/ Fri, 07 Dec 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181207070005_13895038/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181129164041_13885842/ Thu, 29 Nov 2018 16:40:41 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181129164041_13885842/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181129163514_13885833/ Thu, 29 Nov 2018 16:35:14 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181129163514_13885833/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181128164049_13884157/ Wed, 28 Nov 2018 16:40:49 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181128164049_13884157/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181128163513_13884144/ Wed, 28 Nov 2018 16:35:13 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181128163513_13884144/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181123164048_13879122/ Fri, 23 Nov 2018 16:40:48 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181123164048_13879122/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181123163539_13879110/ Fri, 23 Nov 2018 16:35:39 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181123163539_13879110/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181121164039_13876045/ Wed, 21 Nov 2018 16:40:39 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181121164039_13876045/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181121163537_13876067/ Wed, 21 Nov 2018 16:35:37 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181121163537_13876067/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181107163516_13859040/ Wed, 07 Nov 2018 16:35:16 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181107163516_13859040/ <![CDATA[RNS press release - Nominated Adviser Status ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181101133800_13851796/ Thu, 01 Nov 2018 13:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20181101133800_13851796/ <![CDATA[News - ImmuPharma boss excited by “blockbuster potential” of Lupuzor ]]> https://www.proactiveinvestors.co.uk/companies/news/205719/immupharma-boss-excited-by-blockbuster-potential-of-lupuzor-205719.html The chief executive of ImmuPharma PLC (LON:IMM) has told investors he is excited by the “blockbuster potential” of the company’s flagship lupus treatment, Lupuzor.

Earlier this month, ImmuPharma signed an agreement which will see it progress with a managed access programme, giving up to 500 lupus sufferers access to Lupuzor for a minimum of two years.

WATCH: ImmuPharma committed to Lupuzor ahead of managed access to programme

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

In April, the drug missed its primary endpoint in a late-stage study, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

After the end of the phase III trial, 62 patients took part in a ‘follow-up’ study – called an open-label extension study. Results from this are expected in the second quarter of 2019.

Full regulatory approval

“It has been a busy period for the board following the announcement of the phase III trial results for Lupuzor in April 2018,” said chief executive Tim McCarthy.

“We were obviously disappointed with the outcome of the phase III trial results but are excited to be progressing the managed access programme with a new strategic partner, which allows lupus patients early access to Lupuzor.

“In the medium term, we remain focused on achieving the full regulatory approval of Lupuzor which we believe has the potential to be a ground-breaking drug for lupus patients with blockbuster potential in commercial terms.”

Nucant cancer programme making progress

Lupuzor isn’t ImmuPharma’s only drug going through the clinic. Its Nucant cancer treatment has yielded “promising results” in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mln stake.

A licence agreement between the two is expected to be signed by the end of the year, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all of the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma said.

Ureka to be divested

As for the firm’s Ureka subsidiary, which is looking to develop treatments for type II diabetes and NASH, the decision was recently made to sell it.

Despite having “exciting and innovative technologies”, the board does not see as part of the long-term strategy.

As a result, the plan is to divest the Bordeaux-based subsidiary whilst still retaining an interest should any of its drugs achieve some commercial success further down the line.

“Our Nucant programme and Ureka subsidiary have been part of our portfolio for a number of years.  We are equally excited by the potential of both,” said McCarthy.

“We believe the strategy we announced earlier this month, together with a robust financial position, will create enhanced value for shareholders going forward.”

Well-funded

Speaking of that “robust financial position”, thanks to a £10mln fundraise in January, ImmuPharma had £9.0mln of cash in the bank (H1 17: £2.7mln) at the end of June. Net assets grew to £9.9mln (H1 17: £3.6mln).

The company posted a loss for the six months to June 30 of £4.1mln, up from £3.0mln a year ago, reflecting a slight rise in R&D costs.

]]>
Wed, 26 Sep 2018 07:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205719/immupharma-boss-excited-by-blockbuster-potential-of-lupuzor-205719.html
<![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180926070002_13804481/ Wed, 26 Sep 2018 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180926070002_13804481/ <![CDATA[News - Managed access programmes offer an alternative way forward for drug companies ]]> https://www.proactiveinvestors.co.uk/companies/news/205331/managed-access-programmes-offer-an-alternative-way-forward-for-drug-companies-205331.html Managed access programmes (MAPs) have been around for some time, offering poorly people access to drugs that aren’t currently fully licensed or are unavailable in a particular country.

Patients often receive the new, unapproved medication on compassionate grounds, while the MAPs themselves tend to be overseen by specialist drugs firms.

Here in the UK, Clinigen has run over 250 programmes providing ‘off-label’ treatments to those in acute medical need.

Eighteen of the top 20 big pharmaceutical companies now provide early access to their drugs.

Source of rich data 

In fact, MAPs are becoming a rich data source with patient-reported outcome information bundled up with the stats gleaned from clinical trials, which is then submitted to the regulator.

“Merck ran a MAP programme for Keytruda that formed an invaluable part of the regulatory filing that they were able to get reimbursement on,” said Tim McCarthy, chairman of ImmuPharma (LON:IMM).

Keytruda is one of a new breed of immunotherapy drugs that could help revolutionise the treatment of the killer disease.

McCarthy’s reference to the Merck breakthrough was by way of example as of what can be achieved using MAPs as ImmuPharma prepares to go down the same route.

500 patients to be treated

It will offer 500 patients with the autoimmune disease lupus access to Lupuzor, which generated mixed data in phase III clinical trial.

“We can get valuable data on the drug,” McCarthy told Proactive’s, Andrew Scott.

“We call this real-world data. I should stress, this is not a clinical study. All patients will get the drug, there will be no comparator group, blinding or randomisation.”

The MAP will be around a tenth of the cost of the last ImmuPharma clinical with patients receiving the medication free of charge for two years.

“This approach is getting a lot of traction now in our industry,” said McCarthy.

FOR THE FULL PROACTIVE INTERVIEW CLICK THIS LINK 

Despite the phase III setback for Lupuzor, ImmuPharma still plans to make a regulatory filing.

]]>
Thu, 20 Sep 2018 12:49:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205331/managed-access-programmes-offer-an-alternative-way-forward-for-drug-companies-205331.html
<![CDATA[RNS press release - Appointment of Joint Brokers ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180919070005_13795823/ Wed, 19 Sep 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180919070005_13795823/ <![CDATA[Media files - ImmuPharma firmly committed to Lupuzor ahead of managed access programme ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10512/immupharma-firmly-committed-to-lupuzor-ahead-of-managed-access-programme-10512.html Tue, 18 Sep 2018 14:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10512/immupharma-firmly-committed-to-lupuzor-ahead-of-managed-access-programme-10512.html <![CDATA[News - ImmuPharma’s flagship lupus drug to be made available to patients ahead of regulatory filing ]]> https://www.proactiveinvestors.co.uk/companies/news/204410/immupharmas-flagship-lupus-drug-to-be-made-available-to-patients-ahead-of-regulatory-filing-204410.html Some lupus patients will soon have access to a potentially “ground-breaking” new treatment after Immupharma PLC (LON:IMM) signed an agreement which will see it press ahead with a managed access programme (MAP).

The deal with a specialist provider will allow up to 500 sufferers ongoing access to Immupharma’s flagship drug, Lupuzor, for a minimum of two years.

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

WATCH: ImmuPharma firmly committed to Lupuzor ahead of managed access programme

Earlier this year, the drug missed its primary endpoint in a late-stage study, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

After the end of the phase III trial, 62 patients took part in a ‘follow-up’ study – called an open-label extension study. Results from this are expected in the second quarter of 2019.

READ: ImmuPharma says pre-clinical study points to other indications for Lupuzor

“The board has been focused on delivering a business strategy which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, resources and know-how,” said chairman Tim McCarthy.

“We are excited as a team to be progressing the MAP programme which allows Lupus patients early access to Lupuzor.

“In the medium term, we remain focused on achieving the full regulatory approval of Lupuzor which we believe has the potential to be a ground-breaking drug for Lupus patients and in turn has blockbuster potential in commercial terms.”

Nucant cancer programme making progress

Lupuzor isn’t ImmuPharma’s only drug going through the clinic. Its Nucant cancer treatment has yielded “promising results” in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mln stake.

A licence agreement between the two is expected to be signed by the end of the year, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all of the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma said.

Ureka to be divested

As for the firm’s Ureka subsidiary, which is looking to develop treatments for type II diabetes and NASH, the decision has been made to sell it.

Despite having “exciting and innovative technologies”, the board does not see as part of the long-term strategy.

As a result, the plan is to divest the Bordeaux-based subsidiary whilst still retaining an interest should any of its drugs achieve some commercial success further down the line.

“Our Nucant programme and Ureka subsidiary have been part of our portfolio for a number of years,” added McCarthy.

“We are equally excited by the potential of both. We believe the strategy we have announced today for both, will create enhanced value for shareholders going forward.”

]]>
Fri, 07 Sep 2018 08:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/204410/immupharmas-flagship-lupus-drug-to-be-made-available-to-patients-ahead-of-regulatory-filing-204410.html
<![CDATA[RNS press release - Corporate Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180907070003_13782249/ Fri, 07 Sep 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180907070003_13782249/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180710164026_13712790/ Tue, 10 Jul 2018 16:40:26 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180710164026_13712790/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180710163513_13712782/ Tue, 10 Jul 2018 16:35:13 +0100 https://www.proactiveinvestors.co.uk/companies/rns/463/LSE20180710163513_13712782/